Description:AZD-2014, also known as a selective inhibitor of the mTOR (mechanistic target of rapamycin) pathway, is a compound that has garnered attention in the field of cancer research. It is classified as a small molecule and is primarily investigated for its potential therapeutic applications in various malignancies, particularly those with dysregulated mTOR signaling. The substance exhibits characteristics typical of mTOR inhibitors, including the ability to impede cell proliferation and induce apoptosis in cancer cells. AZD-2014 has shown promise in preclinical studies, demonstrating efficacy in inhibiting tumor growth and enhancing the effects of other anticancer agents. Its mechanism of action involves the disruption of the mTOR signaling cascade, which plays a crucial role in cell growth, metabolism, and survival. Additionally, AZD-2014 is characterized by its pharmacokinetic properties, which influence its absorption, distribution, metabolism, and excretion in biological systems. Ongoing research aims to further elucidate its therapeutic potential and optimize its use in clinical settings.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-](https://static.cymitquimica.com/products/IN/thumb/DA000382.jpg)
